Search

Chitosan-dextran sulfate nanoparticles of acetazolamide were formulated by using the ionic gelation technique, and evaluated for different attributes like particle size, ζ potential, drug entrapment, particle morphology, in vitro drug release, and in vivo efficacy. Particle size was observed to be changed with the increment of the drug/polymer ratio. Sustained in vitro drug release was exhibited by the particulate formulation that followed the Korsmeyer-Peppas kinetic model. Drug release from nanoparticles was found to occur, as shown by the results, through a combination of dissolution and diffusion. The optimized formulation had a particle size of 172.3 nm and ζ potential of 36.46 mV. The particles had a spherical shape and polydispersity index of 0.257. Decrease in crystallinity of the drug was indicated by powder X-ray diffraction and differential scanning calorimetry studies, in the optimized nanoparticle formulation. Approximately 2.5 times higher transcorneal permeation of drug was observed across the excised goat cornea, in comparison to the aqueous solution of drug, without any corneal damage, during ex vivo transcorneal studies. In vitro mucoadhesion studies showed 91.59% mucoadhesion. The in vivo studies involving ocular hypotensive activity in rabbits revealed significantly higher hypotensive activity with a p-value of

The aim of the present study was to develop and evaluate positively charged nanoparticles of aceclofenac for ocular delivery. The nanoparticles were prepared by the nanoprecipitation method using Eudragit RS 100. The optimized nanoparticles were found to have narrow particle size range (238.9 ± 8 nm) with nearly spherical shape, positive zeta potential (40.3 ± 3.8). Higher entrapment efficiency of aceclofenac (94.53 ± 1.0%) with prolonged in vitro drug release profiles was also observed. Powder X-ray diffraction and differential scanning calorimetry studies indicated decrease in crystallinity of drug within the nanoparticulate polymeric matrix. The formulation was found to have higher permeation as compared to aceclofenac aqueous solution. Nanoparticle formulation was found to be quite stable and well tolerated with no signs of corneal damage. The in vivo studies involving the arachidonic acid-induced ocular inflammation in rabbits showed optimal efficacy of the nanoparticles with significantly higher inhibition of polymorphonuclear leukocytes migration (p < 0.05) and lid closure scores. [ABSTRACT FROM AUTHOR]

Ocular inflammatory diseases, such as uveitis, scleritis, episcleritis and dry eye syndrome are commonly treated with eye drop formulations. In the present study, attempts were made to prepare aceclofenac oil formulations to evaluate its transcorneal permeation and anti-inflammatory effect. Ophthalmic solutions of aceclofenac with or without (0.5% v/v) benzyl alcohol were formulated in different vegetable oils and permeation studies were carried out. Aceclofenac ophthalmic solution in linseed oil containing benzyl alcohol exhibited maximum permeation (4.42% in goat, 4.26% in sheep and 3.94% in buffalo) through corneas under study. The partition characteristics of aceclofenac in linseed oil reinforced the results of permeation studies. The optimized formulation (linseed oil containing benzyl alcohol) showed better stability profile. Linseed oil aceclofenac formulation showed significant inhibitory effect on ocular inflammation induced by arachidonic acid in rabbit eyes (p < .05) and hence it can be considered as a potential approach for treatment of ocular inflammatory conditions. [ABSTRACT FROM PUBLISHER]

Colon-targeted microparticles loaded with a model anti-inflammatory drug were fabricated using especially designed acrylic acid–butyl methacrylate copolymers. Microparticles were prepared by oil-in-oil solvent evaporation method using Span 80 as emulsifier. Microparticles were found to be spherical in shape, hemocompatible and anionic with zeta potential of −27.4 and −29.0 mV. Entrapment of drug in the microparticles was confirmed by Fourier transform infrared (FTIR) spectroscopy. However, X-ray diffraction (XRD) and differential scanning calorimetry (DSC) revealed amorphous nature of microparticles due to the dilution effect of amorphous polymer. The microparticles released less than 5% drug at pH 1.2, while more than 90% of the drug load was released at pH 7.4. This suggested the colon targeting nature of the formulations. In experimentally developed colitis in Wistar rats, the microparticle formulation showed significant reduction (p < .05) in the disease activity score (disease symptoms), the colon-to-body weight ratio (tissue edema) and the myeloperoxidase, tumor necrosis factor (TNF)-α and interleukin (IL)-1β activities. [ABSTRACT FROM AUTHOR]

Hydrophilic monomer methacrylic acid was copolymerized with hydrophobic monomer butylmethacrylate in different molar ratio, using AIBNfree radical initiator. Successful polymerization was confirmed by FTIR and1H NMR, while DSC and XRD revealed the amorphous nature of the polymers. Copolymers were highly hemocompatible. The polymers showed pH-dependent swelling and erosion which increased with increase in pH. As the amount of methacrylic acid increased, the swelling and erosion also increased. Polymers were used for the microencapsulation of a model anti-inflammatory drug, aceclofenac by an oil-in-oil solvent evaporation method. Microparticles were characterized using FTIR, XRD, DSC, and SEM analysis. The negatively charged particles were almost spherical in shape. The drug release was best explained by zero-order kinetics with anomalous release mechanism. Less than 1% of drug was released at pH 1.2 while the bulk of the drug load was released at pH 6.8 or above, confirming the colon-targeting nature. The microparticles showed significant lowering in myeloperoxidase activity in trinitrobenzene sulfonic acid-induced colitis rat model. There was a significant lowering in the severity of disease symptoms and colon-to-body weight ratio. The histopathological studies also confirmed successful treatment with microparticle formulation. [ABSTRACT FROM PUBLISHER]

In the current study, polylactide-co-glycolide (PLGA) nanoparticles entrapping both clozapine (CLZ) and risperidone (RIS) were formulated by spray-drying using Buchi Nano Spray Dryer B-90 (Flawil, Switzerland). Parameters such as inlet temperature, spray mesh diameter, sample flow rate, spray rate and applied pressure were optimized to produce nanoparticles having desired release profile using both low- and high-molecular weight PLGA polymer. Smallest size nanoparticle of size around 248 nm could be prepared using a 4.0 μm mesh diameter with low-molecular weight polymer. The load of CLZ and RIS was 126.3 and 58.2 μg/mg of polymer particles, respectively. Entrapment efficiency of drugs in PLGA nanoparticles was 94.74% for CLZ and 93.12% for RIS. Both the drugs released continuously from the nanoparticle formulations. PLGA nanoparticles formulated using low-molecular weight polymer released around 80% of the entrapped drug over 10 days of time. Nature of drug inside polymer particles was amorphous, and there was no chemical interaction of CLZ and RIS with polymer. Polymeric nanoparticles were found to be non-toxic in nature using PC12 cell line. This nanospray drying process proved to be suitable for developing polymeric nanoformulation delivering dual drugs for the treatment of Schizophrenia. [ABSTRACT FROM AUTHOR]